EDAP TMS Continues Ablatherm-HIFU Leadership at AUA

EDAP TMS Continues Ablatherm-HIFU Leadership at AUA
Company to Present at June 2005 6th International Consultation on New
Developments in Prostate Cancer and Prostate Disease and BAUS Conferences 


LYON, France, June 3  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), is
pleased to report successful continuation of its education efforts relating to
the advancement of HIFU technology in combating prostate cancer at the American
Urology Association (A.U.A.) meeting, held May 24-27, in San Antonio, Texas.

The annual event gathered more than 6,000 attendees from the urology field. 
Three abstracts relating to the efficacy of HIFU as a treatment option were
presented by Ablatherm-HIFU users Dr. Albert Gelet, Dr. Stefan Thueroff and Pr.
Christian Chaussy.

   * Dr. Gelet, from Edouard Herriot Hospital, Lyon, presented an abstract
     entitled "Prostate Cancer Control with Transrectal HIFU in
     230 Patients: Five-Year Results," outlining an 86 percent success rate
     and substantially lower side effect rates upon treatment
     standardization within the clinical setting.  Primary side effects
     included incontinence falling from 28 percent to 9 percent and bladder
     neck stenosis falling from 31 percent to 6 percent upon standardization
     during the five-year study.  Additionally, Gelet's results indicate
     treatment repeatability of this option remains a unique advantage as
     compared to alternative treatments.
   * Dr. Thueroff, from Harlaching Hospital, Munich, presented the "Efficacy
     of Local High Intensity Focused Ultrasound (HIFU) in Localized Prostate
     Cancer," reporting results of more than 1,000 treatments at a single
     center confirming high efficacy -- up to 93 percent as measured by
     negative biopsies -- and low side effects on three classes of patients
     including high-, medium and low-risk groups.
   * Pr. Chaussy, from Harlaching Hospital, presented a prospective study
     "Side Effects of Transrectal High Intensity Focused Ultrasound (HIFU)
     in the Local Treatment of Prostate Cancer at 8 Years," showing the low
     side effects of local Ablatherm-HIFU in primary cases and proving that
     these minimal side effects can be sustained over the years.



During that meeting, EDAP organized specific daily "Meet the Experts" workshops
inviting American urologists to attend sessions moderated by Pr. Chaussy and
Dr. D'Hont, from A.Z. Middelheim, Antwerp, Belgium.  At these workshops both
Dr. Gelet and Dr. Thueroff shared their experiences with Ablatherm-HIFU on
patients suffering radiotherapy failures and on the five- year results,
respectively.  Attendees showed great interest and enthusiasm for
Ablatherm-HIFU technology.

Also during the AUA conference EDAP introduced the North American market to its
newest enhancement to Ablatherm-HIFU, the integrated imaging system. This
innovative probe allows users to obtain a high quality 3-D image while
simultaneously treating.  This significantly shortens treatment time and offers
increased imaging capability to further refine treatment parameters -- a key
contributor to patient outcomes -- while continuing to lower the incidence of
side effects.

Hugues de Bantel, CEO of EDAP, commented: "Our participation in the AUA
conference continues to demonstrate EDAP's leadership role in the development
and application of HIFU technology to prostate cancer.  Additionally, interest
is growing in the North American market for access to Ablatherm-HIFU as a
treatment alternative to more invasive traditional therapies which also have
higher side effects and are more disruptive to the patient's lifestyle.  The
specific focus of the treatment combined with proven successful results during
long-term studies carried out at multiple centers clearly shows HIFU will be a
focal point of future treatment in combating prostate cancer.  EDAP is pleased
to be recognized as the world leader in the application of HIFU technology to
prostate cancer."

EDAP will also be participating in the 6th International Consultation on New
Developments in Prostate Cancer and Prostate Diseases, co-sponsored by the
International Union Against Cancer, to be held in Paris June 24-27.  The event
will be assessing new trends in the fast developing area of research against
cancer.  Pr. Guy Vallancien, from Institut Mutualiste Monsouris, Paris, will be
reviewing all existing techniques for the treatment of prostate cancer and
present a video session titled "Ablatherm-HIFU for Localized Prostate Cancer:
The Minimally Invasive Alternative for Urologists" as part of EDAP's continuing
efforts to educate the broad urological community about leading- edge
Ablatherm-HIFU treatment.  This presentation will be followed by an interactive
question and answer session.  EDAP invites all interested urologists to attend
this session and inquire about Ablatherm-HIFU.

Finally, EDAP will be present at the B.A.U.S. (British Association of Urology
Surgeons) meeting to be held in Glasgow, Scotland, from June 27 to July 1,
2005.  The company announced on April 1, 2005 the U.K. National Institute for
Clinical Excellence (NICE) approval of guidelines supporting the use of High
Intensity Focused Ultrasound (HIFU) for the treatment of localized prostate
cancer.  The company is continuing to position itself to reach a broader
portion of the U.K. population through expansion of its clinical partners and
physician and patient education.  EDAP has been treating U.K. patients for more
than a year from its launch clinic at Stepping Hill Hospital in Stockport under
the direction of Dr. Stephen Brown.

"EDAP continues to break down barriers of education and visibility in the use
of Ablatherm-HIFU technology as the preferred treatment for prostate cancer,"
de Bantel commented.  "We continue to make significant progress on multiple
fronts in making this treatment more accessible to both patients and urologists
by gaining regulatory approvals, continuing to work toward appropriate
reimbursement and providing innovative business models tailored to the needs of
local clinics so they can offer this highly effective treatment to their
patient population."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically
proven choice for High Intensity Focused Ultrasound (HIFU) treatment of
localized prostate cancer.  HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects.  The
company is also developing this technology for the treatment of certain other
types of tumors.  EDAP TMS S.A. also produces and commercializes medical
equipment for treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL).

For more information on the Company, contact the Investor Relations Dept by
phone at [phone] or see the Company's Web site at:
http://www.edap-tms.com/ .

This press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties.  These include
statements regarding the Company's growth and expansion plans.  Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in the forward-looking statements.  Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission.

   CONTACT:  EDAP TMS S.A.
             Hugues de Bantel - Philippe Chauveau
             Blandine Confort
             [phone]

             Halliburton Investor Relations
             Matt Kreps - Geralyn DeBusk
             972 458 8000


DATASOURCE: EDAP TMS S.A.



CONTACT:  Hugues de Bantel, Philippe Chauveau, or Blandine Confort, all

of EDAP TMS S.A., [phone]; or Matt Kreps or Geralyn DeBusk, both of

Halliburton Investor Relations, [phone], for EDAP TMS S.A.



Web site:  http://www.edap-tms.com/ 

Copyright